×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
FGEN – fibrogen, inc (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
FGEN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/2
07:07 pm
fgen
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit [Yahoo! Finance]
Low
Report
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit [Yahoo! Finance]
12/2
04:05 pm
fgen
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit
Low
Report
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit
11/11
12:30 am
fgen
FibroGen Inc (FGEN) Q3 2025 Earnings Call Highlights: Strategic Moves Bolster Financial ... [Yahoo! Finance]
High
Report
FibroGen Inc (FGEN) Q3 2025 Earnings Call Highlights: Strategic Moves Bolster Financial ... [Yahoo! Finance]
11/10
10:02 pm
fgen
FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/10
04:32 pm
fgen
FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
11/10
04:02 pm
fgen
FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update
11/3
04:02 pm
fgen
FibroGen to Report Third Quarter 2025 Financial Results
Low
Report
FibroGen to Report Third Quarter 2025 Financial Results
10/7
07:36 am
fgen
Progentos Therapeutics Names Paul Frohna Chief Medical Officer [Yahoo! Finance]
Medium
Report
Progentos Therapeutics Names Paul Frohna Chief Medical Officer [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/17
04:43 pm
fgen
Form 4 FIBROGEN INC For: Nov 13 Filed by: Wettig Thane
Medium
Report
Form 4 FIBROGEN INC For: Nov 13 Filed by: Wettig Thane
11/14
06:42 pm
fgen
Form SCHEDULE 13G/A FIBROGEN INC Filed by: ARMISTICE CAPITAL, LLC
Medium
Report
Form SCHEDULE 13G/A FIBROGEN INC Filed by: ARMISTICE CAPITAL, LLC
11/10
04:11 pm
fgen
Form 10-Q FIBROGEN INC For: Sep 30
Medium
Report
Form 10-Q FIBROGEN INC For: Sep 30
11/10
04:06 pm
fgen
Form 8-K FIBROGEN INC For: Nov 10
Medium
Report
Form 8-K FIBROGEN INC For: Nov 10
11/6
04:14 pm
fgen
Form 8-K FIBROGEN INC For: Nov 06
Low
Report
Form 8-K FIBROGEN INC For: Nov 06
9/9
07:26 pm
fgen
Form 4 FIBROGEN INC For: Jun 06 Filed by: DeLucia David
Low
Report
Form 4 FIBROGEN INC For: Jun 06 Filed by: DeLucia David
9/9
07:25 pm
fgen
Form 4 FIBROGEN INC For: Jun 06 Filed by: Wettig Thane
Low
Report
Form 4 FIBROGEN INC For: Jun 06 Filed by: Wettig Thane
9/5
05:04 pm
fgen
Form 8-K FIBROGEN INC For: Aug 29
Medium
Report
Form 8-K FIBROGEN INC For: Aug 29
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/8
FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease
20.6%
9/18 Form 4 FIBROGEN INC For: Sep 17 Filed by: Cotroneo Pat 18.0%
5/9 FibroGen Announces Positive Topline Results from Pooled Safety Analyses of Roxadustat Global Phase 3 Program 13.5%
3/19 FibroGen Inc (NASDAQ: FGEN) had its price target lowered by analysts at Citigroup Inc from $65.00 to $51.00. They now have a "buy" rating on the stock. 12.5%
3/23 Form 4 FIBROGEN INC For: Mar 19 Filed by: KEARNS THOMAS F JR 12.4%
3/26 FibroGen Inc (NASDAQ: FGEN) was downgraded by analysts at TheStreet from a "c-" rating to a "d" rating. 7.7%
8/26 Fibrogen Announces Passing of CEO Thomas B. Neff, Scientific Innovator and Pioneering Biopharmaceutical Executive 7.4%
2/5 FibroGen Inc (NASDAQ: FGEN) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 6.0%
6/14 Form 4 FIBROGEN INC For: Jun 12 Filed by: Yu K Peony 5.7%
11/14 FibroGen Inc (NASDAQ: FGEN) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 5.3%
9/18 Form 4 FIBROGEN INC For: Sep 17 Filed by: Cotroneo Pat 18.0%
5/9 FibroGen Announces Positive Topline Results from Pooled Safety Analyses of Roxadustat Global Phase 3 Program 13.5%
3/19 FibroGen Inc (NASDAQ: FGEN) had its price target lowered by analysts at Citigroup Inc from $65.00 to $51.00. They now have a "buy" rating on the stock. 12.5%
3/23 Form 4 FIBROGEN INC For: Mar 19 Filed by: KEARNS THOMAS F JR 12.4%
3/26 FibroGen Inc (NASDAQ: FGEN) was downgraded by analysts at TheStreet from a "c-" rating to a "d" rating. 7.7%
8/26 Fibrogen Announces Passing of CEO Thomas B. Neff, Scientific Innovator and Pioneering Biopharmaceutical Executive 7.4%
2/5 FibroGen Inc (NASDAQ: FGEN) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 6.0%
6/14 Form 4 FIBROGEN INC For: Jun 12 Filed by: Yu K Peony 5.7%
11/14 FibroGen Inc (NASDAQ: FGEN) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 5.3%
TOP News Decliners
5/9
Form 8-K FIBROGEN INC For: May 09
-27.0%
11/11 FibroGen Inc (NASDAQ: FGEN) had its "positive" rating re-affirmed by analysts at Mizuho. They now have a $72.00 price target on the stock, up previously from $65.00. -15.5%
3/18 FibroGen Inc (NASDAQ: FGEN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -12.1%
3/2 Form S-3ASR FIBROGEN INC -8.6%
11/4 FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019 -7.5%
9/23 Form 4 FIBROGEN INC For: Sep 19 Filed by: Chung Christine -6.8%
8/14 FibroGen Inc (NASDAQ: FGEN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $51.00 price target on the stock. -6.6%
8/8 FibroGen Reports Second Quarter 2019 Financial Results -6.5%
5/6 FibroGen to Report First Quarter 2019 Financial Results -6.0%
3/19 Form 4 FIBROGEN INC For: Mar 06 Filed by: Chung Christine -5.1%
11/11 FibroGen Inc (NASDAQ: FGEN) had its "positive" rating re-affirmed by analysts at Mizuho. They now have a $72.00 price target on the stock, up previously from $65.00. -15.5%
3/18 FibroGen Inc (NASDAQ: FGEN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -12.1%
3/2 Form S-3ASR FIBROGEN INC -8.6%
11/4 FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019 -7.5%
9/23 Form 4 FIBROGEN INC For: Sep 19 Filed by: Chung Christine -6.8%
8/14 FibroGen Inc (NASDAQ: FGEN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $51.00 price target on the stock. -6.6%
8/8 FibroGen Reports Second Quarter 2019 Financial Results -6.5%
5/6 FibroGen to Report First Quarter 2019 Financial Results -6.0%
3/19 Form 4 FIBROGEN INC For: Mar 06 Filed by: Chung Christine -5.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: